江(jiang)蘇(su)萬(wan)(wan)邦(bang)生(sheng)化醫(yi)藥(yao)(yao)集(ji)團(tuan)有限責(ze)任公(gong)(gong)司(si)（簡(jian)(jian)稱萬(wan)(wan)邦(bang)醫(yi)藥(yao)(yao)）系上海復星醫(yi)藥(yao)(yao)（集(ji)團(tuan)）股(gu)份有限公(gong)(gong)司(si)（簡(jian)(jian)稱復星醫(yi)藥(yao)(yao)，股(gu)票代碼：600196-SH，02196-HK）核心成員企業。公(gong)(gong)司(si)前身為(wei)(wei)(wei)成立(li)(li)于(yu)(yu)1981年(nian)的(de)徐州生(sheng)物化學(xue)制(zhi)(zhi)藥(yao)(yao)廠；1998年(nian)改制(zhi)(zhi)為(wei)(wei)(wei)徐州萬(wan)(wan)邦(bang)生(sheng)化制(zhi)(zhi)藥(yao)(yao)有限公(gong)(gong)司(si)；2001年(nian)變更(geng)為(wei)(wei)(wei)江(jiang)蘇(su)萬(wan)(wan)邦(bang)生(sheng)化醫(yi)藥(yao)(yao)股(gu)份有限公(gong)(gong)司(si)；2004年(nian)加入(ru)復星醫(yi)藥(yao)(yao)；2017年(nian)升級為(wei)(wei)(wei)江(jiang)蘇(su)萬(wan)(wan)邦(bang)生(sheng)化醫(yi)藥(yao)(yao)集(ji)團(tuan)有限責(ze)任公(gong)(gong)司(si)。 萬(wan)(wan)邦(bang)醫(yi)藥(yao)(yao)建有國(guo)內一流(liu)的(de)原(yuan)核和(he)(he)真核細胞基因工程(cheng)藥(yao)(yao)物研發和(he)(he)生(sheng)產基地，重(zhong)(zhong)組人胰(yi)島素(su)及類(lei)似物、重(zhong)(zhong)組人促紅細胞生(sheng)成素(su)等(deng)重(zhong)(zhong)組蛋白藥(yao)(yao)物的(de)研發國(guo)內領先(xian)；通過參股(gu)，在(zai)美國(guo)的(de)舊金(jin)山建立(li)(li)了小(xiao)分(fen)子創新藥(yao)(yao)研發實驗(yan)室；在(zai)小(xiao)分(fen)子高難度仿制(zhi)(zhi)藥(yao)(yao)方(fang)面亦處(chu)于(yu)(yu)行(xing)業領先(xian)地位(wei)。公(gong)(gong)司(si)年(nian)投入(ru)約占當(dang)年(nian)銷售收入(ru)10％的(de)資金(jin)用于(yu)(yu)新品研發；擁有近300人的(de)專(zhuan)職(zhi)研發隊伍，其中38%以上為(wei)(wei)(wei)碩士博士等(deng)高層次人員，年(nian)均(jun)申請國(guo)家專(zhuan)利四十余項，每年(nian)有數個新產品上市(shi)。